Manuka, Inc. Stock

Equities

MNKA

US04302Q1094

Biotechnology & Medical Research

Market Closed - OTC Markets 09:30:02 2024-04-25 am EDT 5-day change 1st Jan Change
0.04 USD -20.00% Intraday chart for Manuka, Inc. -20.00% -44.44%
Sales 2021 0.01 Sales 2022 0.31 Capitalization 130M
Net income 2021 - Net income 2022 -1M EV / Sales 2021 * -
Net cash position 2021 78.02K Net Debt 2022 301K EV / Sales 2022 418,843,518 x
P/E ratio 2021 *
-
P/E ratio 2022
-48.8 x
Employees 4
Yield 2021 *
-
Yield 2022
-
Free-Float 12.93%
More Fundamentals * Assessed data
Dynamic Chart
Manuka, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Manuka, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Manuka, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Artemis Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Artemis Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
Artemis Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Artemis Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Artemis Therapeutics Inc. Announces Executive Changes CI
Manuka Ltd completed the acquisition of Artemis Therapeutics Inc. in a reverse merger transaction. CI
Artemis Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Manuka Ltd entered into a share exchange agreement to acquire Artemis Therapeutics Inc. for $92.4 million in a reverse merger transaction. CI
Artemis Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Artemis Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
Artemis Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Artemis Therapeutics Inc. Issues Two Unsecured Promissory Notes CI
More news
1 day-20.00%
1 week-20.00%
Current month-20.00%
1 month-20.00%
3 months-55.56%
6 months-43.66%
Current year-44.44%
More quotes
1 week
0.04
Extreme 0.04
0.04
1 month
0.04
Extreme 0.04
0.04
Current year
0.04
Extreme 0.04
0.11
1 year
0.01
Extreme 0.01
1.89
3 years
0.01
Extreme 0.01
3.75
5 years
0.01
Extreme 0.01
3.75
10 years
0.01
Extreme 0.01
3.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 22-06-29
Director of Finance/CFO 60 22-07-25
Chief Tech/Sci/R&D Officer 66 16-08-01
Members of the board TitleAgeSince
Chief Executive Officer 70 22-06-29
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, April 25, 2024 at 09:30 am EDT

More quotes
Manuka, Inc., formerly Artemis Therapeutics, Inc., is focused on offering facial skincare products based on Manuka honey and bee venom. The Company’s products include Face Serum with Manuka Honey and Bee Venom, Face Serum with Enhanced Vitamin C, Day Cream, Nourishing Night Cream with Manuka Honey and Nee Venom, Eye Cream with Manuka Honey and Bee Venom, Face Cleanser Gel and Face Serum. Its Face Serum with Manuka Honey and Bee Venom supports blurring and reduces skin wrinkles. It regenerates skin cells and gives a young and vital appearance to the skin. The bee venom encourages natural skin revival, boosts production of Collagen, enhances skin elasticity and has healing properties for damages skin cells.
More about the company